Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Broad Institute wins appeal to restore CRISPR patent in Europe
Europe
Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.   26 June 2025
AstraZeneca forced to clarify deal terms in row with university
Europe
AstraZeneca and Kudos must disclose alternative deal structures by October 2025 | Ruling aims to clarify counterfactual damages defence ahead of expert meetings.   24 June 2025
UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung
Europe
Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market.   20 June 2025
Americas
Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.   19 June 2025
Careers
Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech.   19 June 2025
Americas
Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.   17 June 2025
Europe
Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.   13 June 2025
Careers
Three seasoned lawyers with experience in biotech, pharmaceutical, and medical device patent matters join the firm's practice in Washington, DC and Chicago offices.   12 June 2025
Americas
With nearly four decades of patent law experience—including decades at the USPTO—new senior patent counsel joins the firm’s Washington, DC office, bringing expertise in biotech, pharma, and chemical engineering.   5 June 2025
Europe
Survey launched ahead of LSIPR’s LSPN Europe conference | Seeks input on AI impact, Brexit, and Unitary Patent system | Focuses on patent challenges in pharma, biotech, medical devices, diagnostics to shape conference discussions in London.   4 June 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.